ScholarLens Back to search
2011•Current Hematologic Malignancy ReportsRequires access

Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy

Deborah L. White, Timothy P. Hughes

Open publisher page 14 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 14 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Nilotinib, Dasatinib, Imatinib, Medicine, Tyrosine-kinase inhibitor, Chronic myelogenous leukemia, Tyrosine kinase, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy — Research Paper | ScholarLens